Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

For people with a certain sleep disorder, a simple blood test could help predict the development of dementia years before ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

The research findings primarily focus on individuals with a sleep disorder but may have broader implications. A recent study ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

Parkinson’s can cause a condition called Parkinson’s disease dementia. This condition is marked by a decline in thinking, reasoning, and problem-solving. Parkinson’s disease is a progressive ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

Researchers at McGill University found that a blood test originally designed for Alzheimer’s can predict dementia risk in ...